Cerebrolysin
About
About Cerebrolysin
Cerebrolysin is a peptide mixture derived from porcine brain proteins, approved in Europe and Asia for Alzheimer's disease, stroke recovery, and traumatic brain injury. It contains a complex of low-molecular-weight neurotrophic peptides that cross the blood-brain barrier. Clinical trials support its use in vascular dementia and ischemic stroke rehabilitation. In the US it is used off-label via compounding or importation.
Science
Mechanism of Action
Delivers a cocktail of neurotrophic peptides that mimic the actions of BDNF, NGF, and CNTF, promoting neuronal survival, reducing apoptosis, and enhancing synaptic plasticity through multiple receptor pathways.
Dosing
Typical Protocol
5–30 mL IV infusion once daily for 10–20 day cycles; lower doses (1–5 mL) used intramuscularly in optimization protocols.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
No verified providers offering Cerebrolysin yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Cerebrolysin.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.